

## Special Issue

# Drug Discovery, Development, and Synthesis for Glioblastoma

### Message from the Guest Editors

Glioblastoma is the most common and lethal malignant primary brain tumor.

The current initial treatment includes surgery, radiation therapy, medication therapy, or a combination of these therapies. However, the overall survival rate for glioblastoma remains quite low. Many factors, such as tumor heterogeneity, tumor location in a region, and rapid, aggressive tumor relapse, make the treatment more challenging. Finding more efficacious therapies is an urgent issue.

In recent years, significant progress has been made in identifying more effective anti-glioblastoma regimens. While overall mortality rates remain high, our improved understanding of the molecular mechanisms and genetic mutations has led to more promising therapeutic approaches.

Pharmaceuticals invites you to share your expertise in the form of reviews and original articles on the challenges of pharmaceutical treatment for glioblastoma, particularly in drug discovery, development, and synthesis, including drug discovery from natural products, biomolecules, drug modification, small-molecule synthesis, combination therapies, and other pharmaceutical applications.

---

### Guest Editors

Dr. Shizue Mito

Dr. Sue Anne Chew

Prof. Dr. Mitsuhiro Arisawa

---

### Deadline for manuscript submissions

closed (30 July 2025)



## Pharmaceuticals

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.8  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/si/218920](https://mdpi.com/si/218920)

*Pharmaceuticals*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)

[mdpi.com/journal/  
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





# Pharmaceuticals

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.8  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/journal/  
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



## About the Journal

### Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

---

### Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)